Fund shareholders of Regeneron Pharmaceuticals, Inc.
ISIN US75886F1075 · United States · LEI 549300RCBFWIRX3HYQ56
- Fund shareholders
- 1,130
- Of which ETFs
- 315 815 other funds
- Value held
- 30.8B $ 4.1B SEK · 102.9M €
1,130 funds hold this company. This table lists the 1,113 that declare it in a regulatory filing. The other 17 publish their holdings in their own reports. They are not in the table.
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| BINDEX USA SCREENED ÍNDICE (CUBIERTO), FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 155K € | 0.19 % | as of Dec 31, 2025 ↗ | |
| INVERSABADELL 25, FI SABADELL ASSET MANAGEMENT, S.A., S.G.I.I.C. | 143.9K € | 0.02 % | as of Dec 31, 2025 ↗ | |
| INVERSABADELL 50, FI SABADELL ASSET MANAGEMENT, S.A., S.G.I.I.C. | 103.2K € | 0.04 % | as of Dec 31, 2025 ↗ | |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 77.5K € | 2.11 % | as of Dec 31, 2025 ↗ | |
| OCCIDENT PATRIMONIO, FI GESIURIS ASSET MANAGEMENT, SGIIC, S.A. | 65.7K € | 0.75 % | as of Dec 31, 2025 ↗ | |
| NORTH CAPE INVERSIONES, S.A., SICAV ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 56.5K € | 0.45 % | as of Dec 31, 2025 ↗ | |
| PSN MULTIESTRATEGIA, FI PSN MULTIESTRATEGIA/ INTERNACIONAL CALIDAD GESIURIS ASSET MANAGEMENT, SGIIC, S.A. | 42.7K € | 0.67 % | as of Dec 31, 2025 ↗ | |
| ACACIA PREMIUM FI ACACIA INVERSION, SGIIC, S.A. | 42.1K € | 0.27 % | as of Dec 31, 2025 ↗ | |
| SABADELL PLANIFICACION, FI SABADELL ASSET MANAGEMENT, S.A., S.G.I.I.C. | 41.4K € | 0.02 % | as of Dec 31, 2025 ↗ | |
| INVERSABADELL 70, FI SABADELL ASSET MANAGEMENT, S.A., S.G.I.I.C. | 33.5K € | 0.05 % | as of Dec 31, 2025 ↗ | |
| MISTRAL INVERSIONES 536, SICAV, S.A SANTANDER ASSET MANAGEMENT, S.A., SGIIC | 25.6K € | 0.60 % | as of Dec 31, 2025 ↗ | |
| DEEP VALUE INTERNATIONAL, FI GESIURIS ASSET MANAGEMENT, SGIIC, S.A. | 16.4K € | 0.02 % | as of Dec 31, 2025 ↗ | |
| GESTION BOUTIQUE VII, FI GESTION BOUTIQUE VII / TOP QUALITY OPPORTUNITIES ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 13.8K € | 1.09 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Direxion Daily Biotech Top 5 Bull 2X ETF Direxion Shares ETF Trust | 8.55 % | as of Apr 30, 2026 ↗ |
| VanEck Biotech ETF VanEck ETF Trust | 7.51 % | as of Mar 31, 2026 ↗ |
| iShares Biotechnology ETF iShares Trust | 7.21 % | as of Mar 31, 2026 ↗ |
| Amplify Weight Loss Drug & Treatment ETF Amplify ETF Trust | 6.77 % | as of Mar 31, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 6.03 % | as of Feb 28, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 5.46 % | as of Mar 31, 2026 ↗ |
| Longleaf Partners Global Fund Longleaf Partners Funds Trust | 4.83 % | as of Mar 31, 2026 ↗ |
| Longleaf Partners Fund Longleaf Partners Funds Trust | 4.82 % | as of Mar 31, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 4.77 % | as of Apr 30, 2026 ↗ |
| LIVE OAK HEALTH SCIENCES FUND Oak Associates Funds | 4.66 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 1,017 | +69 | 40,397,822 | +6.2 % |
| 2026Q1 | 948 | +29 | 38,042,108 | +7.4 % |
| 2025Q4 | 919 | +31 | 35,427,572 | -7.9 % |
| 2025Q3 | 888 | -76 | 38,464,142 | -8.2 % |
| 2025Q2 | 964 | +29 | 41,897,672 | -1.9 % |
| 2025Q1 | 935 | -91 | 42,717,919 | -8.6 % |
| 2024Q4 | 1,026 | -2 | 46,741,888 | -1.0 % |
| 2024Q3 | 1,028 | +4 | 47,228,499 | +0.0 % |
| 2024Q2 | 1,024 | +25 | 47,204,916 | +4.4 % |
| 2024Q1 | 999 | +5 | 45,210,158 | -5.5 % |
| 2023Q4 | 994 | 47,828,710 |
Institutional managers
1,377 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 8,947,735 | 6.9B $ | as of Mar 31, 2026 |
| STATE STREET CORP | 4,664,478 | 3.6B $ | as of Mar 31, 2026 |
| Dodge & Cox | 4,458,238 | 3.4B $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 4,311,806 | 3.2B $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 2,722,071 | 2.1B $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,607,732 | 2B $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,177,527 | 1.7M $ | as of Mar 31, 2026 |
| Nuveen, LLC | 2,065,064 | 1.6B $ | as of Mar 31, 2026 |
| LOOMIS SAYLES & CO L P | 1,912,310 | 1.5B $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,837,459 | 1.4B $ | as of Mar 31, 2026 |
| Invesco Ltd. | 1,724,478 | 1.3B $ | as of Mar 31, 2026 |
| FMR LLC | 1,518,192 | 1.2B $ | as of Mar 31, 2026 |
| Capital World Investors | 1,419,000 | 1.1B $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 1,319,329 | 1B $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,300,558 | 1B $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 1,231,008 | 946M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,189,584 | 919.1M $ | as of Mar 31, 2026 |
| Amundi | 1,009,798 | 780.2M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 941,941 | 727.8M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 812,236 | 627.6M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 804,508 | 621.6M $ | as of Mar 31, 2026 |
| Bank of New York Mellon Corp | 765,411 | 591.4M $ | as of Mar 31, 2026 |
| Legal & General Group Plc | 732,054 | 565.6M $ | as of Mar 31, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 723,621 | 559.1M $ | as of Mar 31, 2026 |
| DEUTSCHE BANK AG\ | 625,388 | 483.2M $ | as of Mar 31, 2026 |
Declared shareholders of Regeneron Pharmaceuticals, Inc.
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Vanguard Capital Management | 7.37 % | 7,660,810 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Regeneron Pharmaceuticals, Inc.
130 funds declare 156 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Regeneron Pharmaceuticals, Inc.". https://titelia.com/en/stocks/regeneron-pharmaceuticals-inc-US75886F1075